Canada - English - Health Canada

merck canada inc - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 2; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 8; pneumococcal polysaccharide serotype 9n; pneumococcal polysaccharide serotype 9v; pneumococcal polysaccharide serotype 10a; pneumococcal polysaccharide serotype 11a; pneumococcal polysaccharide serotype 12f; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 15b; pneumococcal polysaccharide serotype 17f; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 19f; pneumococcal polysaccharide serotype 20; pneumococcal polysaccharide serotype 22f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 33f - solution - 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg - pneumococcal polysaccharide serotype 1 25mcg; pneumococcal polysaccharide serotype 2 25mcg; pneumococcal polysaccharide serotype 3 25mcg; pneumococcal polysaccharide serotype 4 25mcg; pneumococcal polysaccharide serotype 5 25mcg; pneumococcal polysaccharide serotype 6b 25mcg; pneumococcal polysaccharide serotype 7f 25mcg; pneumococcal polysaccharide serotype 8 25mcg; pneumococcal polysaccharide serotype 9n 25mcg; pneumococcal polysaccharide serotype 9v 25mcg; pneumococcal polysaccharide serotype 10a 25mcg; pneumococcal polysaccharide serotype 11a 25mcg; pneumococcal polysaccharide serotype 12f 25mcg; pneumococcal polysaccharide serotype 14 25mcg; pneumococcal polysaccharide serotype 15b 25mcg; pneumococcal polysaccharide serotype 17f 25mcg; pneumococcal polysaccharide serotype 18c 25mcg; pneumococcal polysaccharide serotype 19a 25mcg; pneumococcal polysaccharide serotype 19f 25mcg; pneumococcal polysaccharide serotype 20 25mcg; pneumococcal polysaccharide serotype 22f 25mcg; pneumococcal polysaccharide serotype 23f 25mcg; pneumococcal polysaccharide serotype 33f 25mcg - vaccines

Canada - English - Health Canada

massachusetts public health biologic laboratories - varicella zoster immunoglobulin (human) - liquid - 100unit - varicella zoster immunoglobulin (human) 100unit - serums

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - measles virus, quantity: 1000 ccid50; rubella virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50; live varicella vaccine, quantity: 1995 pfu - diluent, not applicable - excipient ingredients: water for injections - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - rubella virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50; measles virus, quantity: 1000 ccid50; live varicella vaccine, quantity: 1995 pfu - injection, powder for - excipient ingredients: mannitol; sorbitol; lactose; threonine; serine; proline; glycine; alanine; valine; methionine; isoleucine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.

Canada - English - Health Canada

merck canada inc - pneumococcal polysaccharide serotype 12f; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 15b; pneumococcal polysaccharide serotype 17f; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 19f; pneumococcal polysaccharide serotype 20; pneumococcal polysaccharide serotype 22f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 33f; pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 2; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 8; pneumococcal polysaccharide serotype 9n; pneumococcal polysaccharide serotype 9v; pneumococcal polysaccharide serotype 10a; pneumococcal polysaccharide serotype 11a - solution - 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg; 25mcg - pneumococcal polysaccharide serotype 12f 25mcg; pneumococcal polysaccharide serotype 14 25mcg; pneumococcal polysaccharide serotype 15b 25mcg; pneumococcal polysaccharide serotype 17f 25mcg; pneumococcal polysaccharide serotype 18c 25mcg; pneumococcal polysaccharide serotype 19a 25mcg; pneumococcal polysaccharide serotype 19f 25mcg; pneumococcal polysaccharide serotype 20 25mcg; pneumococcal polysaccharide serotype 22f 25mcg; pneumococcal polysaccharide serotype 23f 25mcg; pneumococcal polysaccharide serotype 33f 25mcg; pneumococcal polysaccharide serotype 1 25mcg; pneumococcal polysaccharide serotype 2 25mcg; pneumococcal polysaccharide serotype 3 25mcg; pneumococcal polysaccharide serotype 4 25mcg; pneumococcal polysaccharide serotype 5 25mcg; pneumococcal polysaccharide serotype 6b 25mcg; pneumococcal polysaccharide serotype 7f 25mcg; pneumococcal polysaccharide serotype 8 25mcg; pneumococcal polysaccharide serotype 9n 25mcg; pneumococcal polysaccharide serotype 9v 25mcg; pneumococcal polysaccharide serotype 10a 25mcg; pneumococcal polysaccharide serotype 11a 25mcg - vaccines

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - live attenuated varicella virus (oka strain) -

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vaccines - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz.the use of shingrix should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - measles virus; rubella virus; mumps virus; varicella vaccine - live -

United States - English - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e antigen (unii: cob9ff6i46) (recombinant varicella zoster virus glycoprotein e antigen - unii:cob9ff6i46) - ge: recombinant varicella zoster virus (vzv) glycoprotein e 50 ug in 0.5 ml - shingrix is a vaccine indicated for prevention of herpes zoster (hz) (shingles):     •    in adults aged 50 years and older.     •    in adults aged 18 years and older who are or will be at increased risk of hz due to immunodeficiency or immunosuppression caused by known disease or therapy. limitations of use : do not administer shingrix to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of shingrix [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the data are insufficient to establish if there is vaccine-associated risk with shingrix in pregnant women. a developmental toxicity study was performed in female rats administered shingrix or the as01b adjuvant alone prior to mating, during g

Israel - English - Ministry of Health

merck serono ltd - cladribine - tablets - cladribine 10 mg - cladribine - mavenclad 10mg tablets is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (ms) as defined by clinical or imaging features